Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting
18:01 EST 10 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Onconova Therapeutics, Inc. today announced three presentations relating
to clinical trials of its Phase III-stage anti-cancer agent, rigosertib
(ON 01910.Na), at the 54th American Society of Hematology (ASH) Annual
Meeting in A...
Other Sources for this Article
Onconova Therapeutics
Benjamin Hoffman, 267-759-3680
bhoffman@onconova.us
or
Media:
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
chris@macbiocom.com
More From BioPortfolio on "Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
